miR‐495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression

Zou, Zhenyou; Zou, Ruyi; Zong, Dan; Shi, Yonghong; Chen, Jinyao; Huang, Jie; Zhu, Jiahui; Chen, Liguan; Bao, Xiaoyan; Liu, Yuan; Liu, Weihao; Huang, Wenhui; Hu, Jingsang; Chen, Zhi; Lao, Xiaojie; Chen, Chaoqun; Huang, Xiaoli; Lu, Yao; Ni, Xueyin; Fang, Daoquan; Wu, Dengqiang; Lu, Shuangshuang; Jiang, Meiyan; Qiu, Chenyang; Wu, Yuya; Qiu, Qisha; Dong, Yanyuan; Su, Yujie; Zhao, Chenmin; Zhong, Zhihe; Cai, Jing; Liang, Yong

doi:10.1111/jcmm.13114

Cited by 53 publications

(41 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Up-regulation of miR-495-3p re-sensitizes drug-resistant ovarian and gastric cancer cells to doxorubicin/paclitaxel combination, and cisplatin resistance is reversed in miR-495-3p over-expressing lung cancer cells [20,46] miR-506-3p CTNNB1 Colorectal cancer Over-expression of miR-506-3p re-sensitizes drug-resistant cells to oxaliplatin [35] miR-508-5p ABCB1, ZNRD1 Gastric cancer Down-regulation of miR-508-5p confers resistance to cisplatin, doxorubicin, vincristine, and 5-fluorouracil [21] miR-514 ABCA1, ABCA10, ABCF2…”

Section: Spin1mentioning

confidence: 99%

MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies

Seo

Moeng

Sim³

et al. 2019

Cells

View full text Add to dashboard Cite

The susceptibility of cancer cells to different types of treatments can be restricted by intrinsic and acquired therapeutic resistance, leading to the failure of cancer regression and remission. To overcome this problem, a combination therapy has been proposed as a fundamental strategy to improve therapeutic responses; however, resistance is still unavoidable. MicroRNA (miRNAs) are associated with cancer therapeutic resistance. The modulation of dysregulated miRNA levels through miRNA-based therapy comprising a replacement or inhibition approach has been proposed to sensitize cancer cells to other anti-cancer therapies. The combination of miRNA-based therapy with other anti-cancer therapies (miRNA-based combinatorial cancer therapy) is attractive, due to the ability of miRNAs to target multiple genes associated with the signaling pathways controlling therapeutic resistance. In this article, we present an overview of recent findings on the role of therapeutic resistance-related miRNAs in different types of cancer. We review the feasibility of utilizing dysregulated miRNAs in cancer cells and extracellular vesicles as potential candidates for miRNA-based combinatorial cancer therapy. We also discuss innate properties of miRNAs that need to be considered for more effective combinatorial cancer therapy.Cells 2020, 9, 29 2 of 32 to confer the ability to acquire CSC properties onto cancer cells, thereby contributing to therapeutic resistance [7]. Moreover, cell-to-cell communication via extracellular vesicles among different types of cells within the cancer microenvironment could affect the efficacy of cancer therapies by delivering miRNAs that regulate various signaling pathways connected to therapeutic resistance [8,9].Combination therapies have been proposed to overcome therapeutic resistance via the combined inhibition of different mechanisms. For example, the combination of cobimetinib and pictilisib was reported to be beneficial for the treatment of colorectal cancer cells. However, resistance is unavoidable even after the combination treatment [10]. Similarly, the simultaneous inhibition of phosphoinositide 3-kinase (PI3K) and a mechanistic target of rapamycin kinase (mTOR) was reported to activate extracellular signal-regulated kinase (ERK), a pro-survival factor, in acute myeloid leukemia [11]. Therefore, it is still necessary to explore new combination strategies to defeat therapeutic resistance. An improved understanding of the cellular basis of cancer therapeutic resistance can further provide promising opportunities to design and develop novel cancer treatment strategies to manage cancers.MicroRNAs (miRNAs) are widely recognized, small, regulatory RNAs modulating numerous intracellular signaling pathways in several diseases, including cancers. Based on the expression levels and intracellular functions of miRNAs, they could act as tumor-suppressive or oncogenic factors in cancer cells [12][13][14]. The abnormal expression of miRNAs is associated with therapeutic resistance in cancer, and the modulation of m...

show abstract

Section: Spin1mentioning

confidence: 99%

MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies

Seo

Moeng

Sim³

et al. 2019

Cells

View full text Add to dashboard Cite

show abstract

“…In addition, SIRT1 inhibition by amurensin G was reported to potentiate the antitumor effect of a Hsp90 inhibitor and enhanced the TRAIL‐mediated killing of HCT‐15 colon cancer cells and K562 leukemia cells, although these effects have not been tested in vivo . It is noteworthy that, despite the reported impressive antitumor potential of this agent, these results have not been independently confirmed by other groups, and the compound has not been tested in other tumor types, such as gastric and ovarian cancer, which are notorious for their high MDR1 expression . The lack of pharmacokinetic and safety studies in humans is a major limitation to asserting the therapeutic potential of this compound.…”

Section: Amurensin Gmentioning

confidence: 99%

Gnetin‐C and other resveratrol oligomers with cancer chemopreventive potential

Espinoza

Inaoka

2017

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Resveratrol has been extensively studied to investigate its biological effects, including its chemopreventive potential against cancer. Over the past decade, various resveratrol oligomers, both naturally occurring and synthetic, have been described. These resveratrol oligomers result from the polymerization of two or more resveratrol units to form dimers, trimers, tetramers, or even more complex derivatives. Some oligomers appear to have antitumor activities that are similar or superior to monomeric resveratrol. In this review, we discuss resveratrol oligomers with anticancer potential, with emphasis on well-characterized compounds, such as the dimer gnetin-C and other oligomers from Gnetum gnemon, whose safety, pharmacokinetic, and biological activities have been studied in humans.

show abstract

“…Tumor suppressor miR-34a has also been shown to sensitize gastric cancer cells to PTX via inhibiting expression of oncoprotein E2F5 [148]. Similarly, ectopic expression of tumor suppressor miR-495 has been found to potentiate PTX-ADR sensitivity in MDR SGC7901R gastric cancer cells through modulating expression of ABCB1 [149].…”

Section: Mirnas and Ptx Resistancementioning

confidence: 99%

Noncoding RNAs in gastric cancer: implications for drug resistance

et al. 2020

View full text Add to dashboard Cite

Gastric cancer is the fourth most common malignancy and the third leading cause of cancer-related deaths worldwide. Advanced gastric cancer patients can notably benefit from chemotherapy including adriamycin, platinum drugs, 5-fluorouracil, vincristine, and paclitaxel as well as targeted therapy drugs. Nevertheless, primary drug resistance or acquisition drug resistance eventually lead to treatment failure and poor outcomes of the gastric cancer patients. The detailed mechanisms involved in gastric cancer drug resistance have been revealed. Interestingly, different noncoding RNAs (ncRNAs), such as microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), are critically involved in gastric cancer development. Multiple lines of evidences demonstrated that ncRNAs play a vital role in gastric cancer resistance to chemotherapy reagents and targeted therapy drugs. In this review, we systematically summarized the emerging role and detailed molecular mechanisms of ncRNAs impact drug resistance of gastric cancer. Additionally, we propose the potential clinical implications of ncRNAs as novel therapeutic targets and prognostic biomarkers for gastric cancer.

show abstract

miR‐495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression

Cited by 53 publications

References 39 publications

MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies

MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies

Gnetin‐C and other resveratrol oligomers with cancer chemopreventive potential

Noncoding RNAs in gastric cancer: implications for drug resistance

Contact Info

Product

Resources

About